A Research Study on Etavopivat in Participants With and Without Liver Disease

Inclusion Criteria: * Male or female. * Age 18 years or above at the time of signing the informed consent. * Body mass index (BMI) between 18.5 and 42.0 kilogram per meter\^2 (kg/m\^2) (both inclusive) at screening. * Body weight greater than or equal to (\>=) 40.0 kilogram (kg) at screening. Specific inclusion criteria only for participants with hepatic impairment: * Participants with chronic (above 6 months), stable (no significant deterioration in hepatic function in last 2 months as determined by the investigator) hepatic impairment classified as Child-Pugh class A, B or C, as assessed by the investigator and which is confirmed and documented by medical history, physical examination and at least one of the following: hepatic ultrasound, computerised axial tomography (CT) scan, magnetic resonance imaging (MRI), and/or liver biopsy. * Participants must be on a stable dose of medication and/or treatment regimen (e.g., no expectations of new medications nor changes to current medications within 14 days of dosing). Specific inclusion criterion only for participants with normal hepatic function: \- Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG), and laboratory safety tests performed during screening visit, as judged by the investigator. Exclusion Criteria: * Known or suspected hypersensitivity to study intervention or related products. * Female who is pregnant, breast-feeding …